Overview
PRQR market data
Price History
PRQR price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.40 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.12 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -333.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.33 – $3.10 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $256.8M · P/B 3.73 · P/S 16.32.
Company News
ProQR Therapeutics Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $10.183M Beat $5.560M EstimateBenzinga · Aug 13, 2026, 12:12 PM
ProQR Form4 Filing Shows CEO Daniel De Boer Buys 200,000 Shares At An Average Price Of $1.77; Increasing Direct Holdings to 500,000 SharesBenzinga · Aug 3, 2026, 8:08 PM
ProQR Therapeutics Files Prospectus For Offering 3.03M Ordinary Shares On Behalf Of Selling ShareholderBenzinga · Jul 6, 2026, 8:15 PM
Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6Benzinga · Jun 29, 2026, 3:05 PM
ON Semiconductor To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For FridayBenzinga · Jun 26, 2026, 1:20 PM
Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3Benzinga · Jun 26, 2026, 12:55 PM
Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial SuccessBenzinga · Jun 25, 2026, 2:01 PM